Addex Therapeutics LTD. (ADXN) — 6-K Filings

All 6-K filings from Addex Therapeutics LTD.. Browse 28 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (28)

Addex Therapeutics Files 6-K Report — Apr 21, 2026 Risk: low
Addex Therapeutics Ltd. filed a Form 6-K on April 21, 2026, reporting information as a foreign issuer. The filing includes a press release as Exhibit 99.1, deta
6-K Filing — Dec 10, 2025
6-K Filing — Dec 4, 2025
Addex Therapeutics Files 6-K with Press Release — Oct 29, 2025 Risk: low
On October 29, 2025, Addex Therapeutics Ltd. issued a press release that is incorporated by reference into their Form 6-K filing. This press release is also bei
Addex Therapeutics Files 6-K, Incorporates Exhibits — Sep 30, 2025 Risk: low
Addex Therapeutics Ltd. filed a Form 6-K on September 30, 2025, reporting on its activities as of June 30, 2025. The filing incorporates by reference exhibits 9
Addex Therapeutics Files Form 6-K with Press Release — Sep 23, 2025 Risk: low
On September 23, 2025, Addex Therapeutics Ltd. issued a press release, attached as Exhibit 99.1 to this Form 6-K filing. This press release is incorporated by r
Addex Therapeutics Files 6-K with Press Release — Jun 30, 2025 Risk: low
On June 30, 2025, Addex Therapeutics Ltd. filed a Form 6-K to report the issuance of a press release. This press release, dated June 30, 2025, is attached as Ex
Addex Therapeutics Files Form 6-K with SEC — Jun 25, 2025 Risk: low
On June 25, 2025, Addex Therapeutics Ltd. announced the issuance of a press release, incorporated by reference as Exhibit 99.1 to this Form 6-K filing. This pre
Addex Therapeutics Files 6-K, Incorporates Exhibits — Jun 20, 2025 Risk: low
Addex Therapeutics Ltd. filed a Form 6-K on June 20, 2025, incorporating by reference Exhibits 99.1 and 99.2 into its existing registration statements on Form F
Addex Therapeutics Files 6-K with Press Release — Jun 6, 2025 Risk: low
On June 6, 2025, Addex Therapeutics Ltd. issued a press release, incorporated as Exhibit 99.1 to this Form 6-K filing. This press release is being incorporated
Addex Therapeutics Files 6-K with Press Release — May 12, 2025 Risk: low
On May 12, 2025, Addex Therapeutics Ltd. issued a press release, attached as Exhibit 99.1 to this Form 6-K filing. This press release is incorporated by referen
Addex Therapeutics Files 6-K with Press Release — Apr 30, 2025 Risk: low
On April 30, 2025, Addex Therapeutics Ltd. issued a press release, attached as Exhibit 99.1 to this Form 6-K filing. This press release is incorporated by refer
Addex Therapeutics Files 6-K, Incorporates Press Release — Apr 25, 2025 Risk: low
On April 25, 2025, Addex Therapeutics Ltd. announced the issuance of a press release, which is incorporated by reference into this Form 6-K filing. This press r
Addex Therapeutics Files Form 6-K with Press Release — Apr 17, 2025 Risk: low
On April 17, 2025, Addex Therapeutics Ltd. issued a press release, incorporated by reference into this Form 6-K filing. This press release is attached as Exhibi
Addex Therapeutics Files 6-K, Incorporates Exhibits — Nov 22, 2024 Risk: low
Addex Therapeutics Ltd. filed a Form 6-K on November 22, 2024, incorporating Exhibits 99.1 and 99.2 into its existing S-8 registration statements (Registration
Addex Therapeutics Files 6-K, Incorporates Press Release — Nov 12, 2024 Risk: low
Addex Therapeutics Ltd. filed a Form 6-K on November 12, 2024, reporting a press release issued on November 11, 2024. This filing is incorporated by reference i
Addex Therapeutics Files 6-K, Incorporates Exhibits — Sep 30, 2024 Risk: low
Addex Therapeutics Ltd. filed a Form 6-K on September 30, 2024, to report information as a foreign private issuer. This filing incorporates by reference exhibit
Addex Therapeutics Files 6-K with Press Release — Sep 19, 2024 Risk: low
On September 19, 2024, Addex Therapeutics Ltd. announced the issuance of a press release. This press release is incorporated by reference into their Form 6-K fi
Addex Therapeutics Files 6-K with Press Release — Aug 27, 2024 Risk: low
On August 27, 2024, Addex Therapeutics Ltd. filed a Form 6-K, incorporating by reference a press release dated the same day. This filing serves as a report of a
Addex Therapeutics Files 6-K with Press Release — Jul 22, 2024 Risk: low
On July 22, 2024, Addex Therapeutics Ltd. announced the issuance of a press release. This press release is incorporated by reference into their Form 6-K filing
Addex Therapeutics Files 6-K with Press Release — Jul 15, 2024 Risk: low
On July 15, 2024, Addex Therapeutics Ltd. announced the issuance of a press release, incorporated as Exhibit 99.1 to this Form 6-K filing. This press release is
Addex Therapeutics Files Form 6-K with Press Release — Jul 1, 2024 Risk: low
On July 1, 2024, Addex Therapeutics Ltd. announced the issuance of a press release, which is incorporated by reference into this Form 6-K filing. The press rele
Addex Therapeutics Files 6-K, Incorporates Exhibits — Jun 6, 2024 Risk: low
Addex Therapeutics Ltd. filed a Form 6-K on June 6, 2024, incorporating by reference Exhibits 99.1 and 99.2 into its existing registration statements on Form F-
Addex Therapeutics Files 6-K with Press Release — Jun 5, 2024 Risk: low
On June 5, 2024, Addex Therapeutics Ltd. announced the issuance of a press release. This press release is attached as Exhibit 99.1 to the Form 6-K filing and is
Addex Therapeutics Files 6-K, Incorporates Press Release — Apr 29, 2024 Risk: low
On April 29, 2024, Addex Therapeutics Ltd. announced the issuance of a press release, incorporated by reference as Exhibit 99.1 to this Form 6-K filing. This pr
Addex Therapeutics Files 6-K with Press Release — Apr 18, 2024 Risk: low
On April 18, 2024, Addex Therapeutics Ltd. announced the issuance of a press release, which is incorporated by reference into this Form 6-K filing. This press r
Addex Therapeutics Files 6-K, Incorporates Press Release — Apr 3, 2024 Risk: low
On April 3, 2024, Addex Therapeutics Ltd. announced the issuance of a press release. This press release is incorporated by reference into their Form 6-K filing
Addex Therapeutics Terminates Cantor Fitzgerald Sales Agreement — Jan 30, 2024
Addex Therapeutics Ltd. terminated its "Controlled Equity Offering SM Sales Agreement" with Cantor Fitzgerald & Co. on January 29, 2024, effective immediately.

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX